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ABSTRACT
The function of DNA-binding proteins is controlled
not just by their abundance, but mainly at the level
of their activity in terms of their interactions with
DNA and protein targets. Moreover, the affinity of
such transcription factors to their target sequences
is often controlled by co-factors and/or modifications
that are not easily assessed from biological samples.
Here, we describe a scalable method for monitoring
protein–DNA interactions on a microarray surface.
This approach was designed to determine the DNA-
binding activity of proteins in crude cell extracts,
complementing conventional expression profiling
arrays. Enzymatic labeling of DNA enables direct
normalization of the protein binding to the microarray,
allowing the estimation of relative binding affinities.
Using DNA sequences covering a range of affinities,
we show that the new microarray-based method
yields binding strength estimates similar to low-
throughput gel mobility-shift assays. The microarray
is also of high sensitivity, as it allows the detection of
a rare DNA-binding protein from breast cancer cells,
the human tumor suppressor AP-2. This approach
thus mediates precise and robust assessment of the
activity of DNA-binding proteins and takes present
DNA-binding assays to a high throughput level.
INTRODUCTION
Transcription factors control most cellular processes by their
coordinated expression and binding to specific regulatory DNA
sequences. They therefore possess a great potential for mis-
regulation leading to developmental aberrations or tumors.
A large class of cancer-linked genes can be assigned to the
DNA-binding proteins. Protein-binding microarrays (PBMs)
have recently been successfully used to analyze the binding
specificity (1) or to identify the binding sites genome-wide (2)
of purified transcription factors. In this study, we developed a
highly sensitive and robust functional assay for DNA-binding
proteins in crude cellular extracts, using double-stranded
DNA microarrays. This approach has very broad application,
and here we have focused on the assessment of the binding
of tumor-suppressors and oncogenes from cell or tissue
extracts. In particular, we demonstrate the feasibility of this
approach using the human transcription factor and tumor
suppressor AP-2.
AP-2 is of special interest because of its versatile and essen-
tial functions in cell growth, cell differentiation and pro-
grammed cell death (3–7). AP-2 family members have been
implicated in the progression, vascularization, metastasis and/
or recurrence of tumors, and they constitute good prognostic
factors for melanoma, breast and prostate cancers (8–11).
Recent studies have revealed that the effect of AP-2 on cancer
prognosis is not simply a question of expression level,
but rather is defined by the regulation of the AP-2 protein
itself, for instance by its interaction with other proteins (12)
or its subcellular localization (9). Alternatively, it is the ratio
of AP-2 relative to other competing transcription factors that is
the relevant prognostic indicator, as it controls the expression
of downstream cancer-linked genes (10,11). These post-
translational effects are not readily detectable using conven-
tional large-scale approaches such as expression profiling or
proteomics, and the association of such proteins to the relevant
target sequences must be probed directly from cell or tissue
extracts. Here we propose a novel application for the high-
throughput analysis of protein–DNA-binding activity with
PBMs, allowing the rapid, sensitive and scalable detection
of relative binding activities and specificities directly from
cellular extracts.
*To whom correspondence should be addressed at Laboratory of Molecular Biotechnology, Station 6, FSB-ISP-ISIC, EPFL, 1015 Lausanne, Switzerland.
Tel: +41 21 693 61 51; Fax: +41 21 693 76 10; Email: Nicolas.Mermod@unil.ch
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
ª The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 8 e79
doi:10.1093/nar/gni079
 Published online May 12, 2005
MATERIALS AND METHODS
Generation of the AP-2 profile
The AP-2 profile constructed for this work (Figure 1A) is
based on the SELEX dataset published by Mohibullah and
co-workers (13) comprising 70 in vitro selected protein-
binding sites. To estimate the weights of the profile we applied
a computational protocol developed for the modeling of the
CTF/NF-1 transcription factor (14), using programs from
the software packages SAM version 1.3.3 (R. Hughey and
A. Krogh, http://www.cse.ucsc.edu/research/compbio/sam.html)
and pftools version 2.2 (P. Bucher, ftp://ftp.isrec.isb-sib.ch/
pub/sib-isrec/pftools/). As part of this procedure, the sequences
were realigned using an expectation-maximization algorithm
(15). This analysis supported only the common spacing classes
N3 and N4 (N1 and N2 in our model) but not the spacing
classes N5 and N6 considered by the authors of the data and
the half-site binding mode. The program pfsearch from the
pftools package was used to compute relative binding scores
for potential binding site sequences with the aid of the profile
shown in Figure 1A.
Construction of DNA fragments
Double-stranded 25 bp DNA molecules containing AP-2
bindings sites were generated by hybridization of two comple-
mentary oligonucleotides (Supplementary Table 1) and cloned
into pBAS. This vector corresponds to pBluescriptSKII+
(Amersham Bioscience), whose multiple cloning site (MCS)
was modified by the deletion of SmaI and ApaI sites (Supple-
mentary Table 1). Hybridized oligonucleotides were inserted
into a HincII, EcoRV or NotI site and correct cloning and
orientation were confirmed by sequence analysis.
Double-stranded DNA fragments for microarray spotting
were generated by PCR amplification using standard protocols
with increased concentrations (1 mM) of primers. Amplifica-
tion with primers 120L (50-GCTCCACCGCGGTGCG-30)
and 120R (50-CTATAGGGCGAATTGGGTAC-30) yielded
fragments of 120 bp length (Figure 1B). Primer 120L carried
a 50-amino-modification for covalent linkage to the array sur-
face. PCR products were purified by isopropanol precipitation
in the presence of 0.6 M NH4-acetate. The dried pellet was
re-suspended in H2O, and the DNA concentration was deter-
mined using Sybr Green I (Molecular Probes).
Gel shift assay
Probes for the gel shift assays were radioactively labeled using
T4 polynucleotide kinase (10 U) and 5 ml gATP for 15 min at
room temperature (RT) for 200 ng double-stranded DNA, i.e.
oligonucleotide or PCR product. Probes were separated from
unincorporated ATP by size exclusion using a Sephadex g50
matrix, and stored in aliquots at20C until use. Unless stated
otherwise, the assay mix per lane contained 2 ng radiolabeled
Figure 1. Bioinformatics prediction profile and microarray standardization tools for AP-2 binding studies. (A) Architecture of the AP-2 profile. The model was
constructed from in vitro DNA binding sequences (13), as described in Materials and methods. It is composed of two palindromic half-sites, each containing 6 nt
positions, with allowed spacing between the half-sites of 1 or 2 bp. The position-specific weights associated with the four possible nucleotides and with the two
possible spacings are indicated within boxes. The resulting consensus sequence is given below. Arrows indicate alternative paths corresponding to different binding
modes. The score of a potential binding site is computed as the sum of the corresponding weights. (B) Construction of microarray DNA probes. Double-stranded
oligonucleotides coding for potential AP-2 binding sequences of various predicted affinities, with profile score of 19, 25, 33, 38 or 58, were cloned into the constant
backbone of pBAS using restriction sites HincII, EcoRV or NotI (black triangles). PCR amplification with primers 120L and 120R (arrows) produced 120 bp products
that were used to spot microarrays. (C) Correlation of computer-predicted binding scores with experimental binding values. Affinity scores computed from the AP-2
profile shown in part (A) were plotted against experimental gel shift binding values expressed as gel shift scores (see Materials and methods). The correlation
coefficient of the profile score and gel shift binding values is 0.99. (D) Enzymatic quantification of microarray-spotted DNA. DNA solutions of indicated
concentrations were spotted onto a microarray surface, immobilized DNA probes were subjected to enzymatic Cy5 labeling and fluorescence was scanned.
Background fluorescence was subtracted from all values, which represent the average fluorescence and SD from four experiments.
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probe (O58), 20 ng unlabeled probe (O58), 2 mg poly(dI–dC),
0.5· TEN and 175 ng GST-AP-2 in 1· AP-2 binding buffer.
The mix was incubated at RT for 1 h to reach equilibrium of
the binding reaction before separation on a 4% polyacrylamide
gel. Autoradiograms were analyzed and quantified using a
Storm 240 (Amersham Bioscience) and ImageQuant software
version 1.2 (Molecular Dynamics). The probe occupancy was
subsequently determined as the ratio of shifted band signal
over total signal (Supplementary Figure 1). Absolute affinity
measurements were performed using competitive gel shift
experiments and calculated from Scatchard plots as described
previously (14,16). Relative binding affinities were determ-
ined in competition assays, where the apparent affinity was
estimated by calculating the competitor-to-probe molar ratio
resulting in 50% probe occupancy (IC50 ratio). Relative bind-
ing affinities were converted to gel shift binding scores and
normalized to that obtained for probe O58 using the principles
described by Roulet et al. 2002 (16), according to the follow-
ing calculation: gel shift score = 58  log10(IC50 ratio) · 50.
Protein expression and purification
Human AP-2a full-length cDNA was cloned into GST-fusion
vector pGEX3X (Amersham Bioscience), resulting in plasmid
pGEX-AP-2, and overexpressed as a GST-fusion protein in
Escherichia coli W3110. Protein expression was induced by
the addition of IPTG during the late exponential growth phase
and cells were harvested 2 h later. Cells were disrupted
by sonication and GST-AP-2 enriched from soluble protein
fraction by binding to a Glutathione Sepharose 4B column
(Amersham Bioscience). After washing the pure fusion pro-
tein was eluted in 100 mM Glutathione, yielding typically
350 ng/ml GST-AP-2 according to the Bradford assay (BioRad
Inc.), and aliquots were stored at 80C.
Protein-binding microarrays
DNA concentration was adjusted to 250 mg/ml, unless other-
wise noted, and mixed 1:1 with 2· spotting buffer (6· SSC;
3 M betaine). Each DNA was spotted in quadruplicate on
different positions of the array. Spotting was performed using
an ESI arrayer (BioRad) at 50–55% humidity and 23C onto
Nexterion aldehyde slides (Schott). Slides were blocked by
washing twice for 2 min in TEN [40 mM Tris–HCl (pH 7.5),
1 mM EDTA, 150 mM NaCl], 10 min in aldehyde blocking
solution, twice for 2 min in TEN, 1 h in 5% powdered skim
milk in 1· phosphate-buffered saline (PBS) with 0.05%
Tween-20 and twice for 2 min in TEN. Use of a high salt
buffer such as TEN is required to retain the double-stranded
structure of the nucleic acids on the slide surface.
The DNA on the array was fluorescently labeled using ter-
minal transferase (TdT, NEB). Slides were pre-incubated in
adenosine mono-phosphate (AMP, 100 ng/ml) in PBS for 1 h.
Subsequently enzymatic treatment was carried out accord-
ing to manufacturer’s instructions in a total volume of 20 ml
using 4 U TdT and 5 mM Cyanine5-ddATP (Perkin Elmer)
under addition of 100 ng/ml AMP in the reaction mix. Slides
were incubated at 37C for 1.5 h, washed twice in TEN and
spun dry.
The AP-2 binding assay was carried out essentially as
described for use with Zn finger proteins (16), apart from
the protein-binding buffer. Unless otherwise noted, 35 ng of
purified GST-AP-2 was diluted in AP-2 binding buffer [2.5 mM
Tris–HCl (pH 8.0), 15 mM KCl, 1 mM MgCl2, 0.025 mM
EDTA, 2.5% glycerol, 0.05% NP40, 50 mg/ml BSA] comple-
mented with 2% powdered skim milk and 2 mg poly(dI–dC).
After washing and antibody binding [first antibody: AP-2a
(C-18): sc-184 from Santa Cruz Biotechnologies; second anti-
body: Cy3-labeled Alexa Fluor 546 goat anti-rabbit IgG (H+L)
from Molecular Probes], the slides were spun dry and scanned
using an Agilent G2566AA scanner (Supplementary Figure 2).
Images were analyzed using ScanAlyze (www.rana.lbl.gov).
After background signal subtraction, normalized binding
activity was determined for each spot and defined as the
Cy3 fluorescence signal (pixel) of the antibody for protein
detection divided by the Cy5 fluorescence signal (pixel) of
the enzymatic DNA labeling multiplied by 100 to correct for
detection sensitivity differences between the two dyes. The
ratio of microarray-bound DNA to protein on these arrays can
be approximately calculated as follows: 35 ng GST-AP-2
binds to 150–200 spots of 1 nl (spot volume) with 125 pg/nl
DNA on the general assumption that 20% of the DNA is
covalently bound to the slide. This results in 8 ng GST-AP-2
binding 1 ng of DNA.
Cell culture and nuclear protein extractions
Hepatocellular carcinoma line HepG2 (ATCC-No. HB-8065)
was cultured according to the supplier’s instructions in
Dulbecco’s MEM with Glutamax-I (Gibco) containing 10%
fetal bovine serum. MCF-7 breast carcinoma cells were cul-
tured in RPMI 1640 medium with Glutamax-I (Gibco) with
10% fetal bovine serum. Transient transfections were carried
out as co-transfections of the pEGFPN1 green fluorescent
protein expression vector (BD Bioscience) and pCMX-AP-2
(17) using 3 mg of each plasmid for the transfection of 400 000
cells. Cells were tested for green fluorescent protein expres-
sion at day 2, reaching a transfection efficiency of usually
20–30%. Nuclear protein extractions were carried out accord-
ing to standard techniques, yielding extracts of 1 mg total
protein per milliliter as determined by a Bradford assay
(BioRad).
RESULTS
Design of an AP-2 binding profile and
DNA-binding sequences
Although a number of AP-2 binding sites have been identified
in an in vitro binding site selection assay (13), an appropriate
computer tool allowing the prediction of AP-2 binding sites
and affinities is not yet available from these data. We therefore
reanalyzed the published binding site data and constructed a
quantitative binding site model based on a generalized profile
(18). This type of descriptor and its construction method have
been successfully applied to the quantitative prediction of
the affinities of a transcription factor for DNA sequences of
variable length, notably CTF/NF-1 (14) and members of the
STAT protein family (19). The resulting binding site profile is
shown in Figure 1A. AP-2a homodimer is known to interact
with target sites of different length (13). It typically binds to a
palindromic DNA sequence motif consisting of two reverse-
complementary half-sites, separated by a short spacer of 1 or
2 bp (parameters N1 and N2 in the profile). Sequences
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consisting of only a single half-site motif also appear to be
weak binding targets according to our analysis. Each of the
above-mentioned binding modes corresponds to a different
profile path. The profile allows the computation of a relative
binding score (supposed to be proportional to log Kd values)
for a potential target site by adding up the weights correspond-
ing to the bases at each position and the weight corresponding
to the spacer class. For instance, the AP-2a profile shown in
Figure 1A assigns a score of 58 to the consensus binding
sequence with highest affinity, TCGCCTXAGGCGA, and a
score of 29 to the optimal half-site, TCGCCT or AGGCGA.
The medium-affinity binding sites referred to in this paper fall
in the range of scores between 33 and 38, and low-affinity sites
score from 19 to 25.
In order to assess the specific DNA-binding affinity of
AP-2 experimentally, and to distinguish it from low-affinity
background binding to any unspecific sequence, we introduced
known binding sites into a common and defined DNA
sequence background. We used a derivative of the pBluescript
SKII+ plasmid, pBAS, for this purpose, first removing poten-
tial AP-2 binding sites that might interfere with our assay
from the polylinker. Such sites were predicted by both
the MatInspector (www.gene-regulation.com) and present
(ISREC, www.isrec.isb-sib.ch) computer tools. Five 25 bp
oligonucleotides containing binding sites of different profile
scores (58, 38, 33, 25 and 19) were cloned into pBAS at each
of the three restriction sites indicated in Figure 1B. Two PCR
primers termed 120L and 120R were designed to amplify the
120 bp portion of the plasmid encompassing the binding sites,
with the 120L primer incorporating an amino (N) link for
immobilization onto the microarray surface. Binding sites
introduced at the HincII restriction site are thus positioned
close to the 120 bp fragment extremity used to attach the
double-stranded DNA to the microarray surface; EcoRV
marks the middle of the fragment, and NotI lies at the far
end of the PCR product generated with the 120L/R primers
(Figure 1B). All possible 120mer PCR-amplified probes were
first tested for their affinity to AP-2 in gel electrophoresis
mobility-shift assays prior to spotting on microarrays
(Supplementary Figure 1), using purified AP-2 expressed as
a fusion to the GST protein in E.coli. Binding affinities were
found to range between 3 nM and 8 mM on the oligonucleotide
probes, as estimated from Scatchard plot analysis. Interaction
with the 120mer probes containing the binding sites in the
central location correlated well with the binding scores
determined from the profile (Figure 1C). Similar findings
were obtained using probes with the binding sequences inser-
ted closer to the probe extremities (data not shown), indicating
that the position and DNA sequence context of the binding
sites do not affect affinity in gel shift assays.
On-chip estimation of immobilized DNA amounts
To compare the specific binding affinity of AP-2 to various
DNA sequences, the amount of DNA effectively linked to the
array and available to proteins must be determined. Quantit-
ative DNA staining using Sybr Green I, as in previous studies
(1,2), remains impractical, as dyes that intercalate between
DNA bases often interfere with protein binding. Thus, we
designed a direct enzymatic labeling of the DNA immobilized
on the array surface. The terminal transferase enzyme was
used to add one fluorescently labeled Cyanine5-ddATP to
the 30 end of the DNA strands. The resulting fluorescent signal
of the DNA spots is 200-fold higher than the low-level back-
ground fluorescence of the array surface. Linearity of the
enzymatic DNA labeling was assessed on microarrays where
all the fragments were spotted at concentrations ranging from
100 to 500 ng/ml, indicating precise and reproducible deter-
mination of the relative amounts of the immobilized DNA
(Figure 1D). Although the relationship between the concen-
tration of the spotted DNA and the fluorescent labeling of the
spots on the microarray is fairly linear, fluorescence is not fully
proportional to the amount of spotted DNA. This may indicate
that only a fraction of the spotted DNA is available for protein
interaction once bound to the microarray surface or it might
reflect saturation effects.
Sequence-specific binding of AP-2 to
microarray DNA probes
In order to assess whether AP-2 binds to double-stranded DNA
immobilized on a microarray following the affinities deter-
mined for free binding sites, we assayed binding to the five
sequences with known affinities (profile score 58–19), with
binding sequences inserted at the three above-mentioned posi-
tions into the constant backbone of pBAS (Figure 1B). The
normalized relative binding activity of the purified AP-2
revealed highly specific interaction, as empty pBAS sequences
used as a negative control showed low (background) signal,
and binding reflected the affinities of AP-2 to the target
sequences as determined by gel shift assays (Figure 2A).
Incubation of the protein with a free specific binding site
as a competitor reduced signal-to-background values, as did
use of non-specific control antibodies that do not recognize
bound AP-2 for fluorescent quantification, further illustrat-
ing sequence-specific interaction of the protein with the
immobilized probes (data not shown).
Estimating protein binding ‘on a chip’ is what characterizes
surface-bound binding assays. We considered the possibility
that, in this type of assay, having one of the binding partners
immobilized on a small surface might skew apparent binding
affinities because of a high local concentration. Therefore we
tested several possibly influential parameters to probe further
the general applicability of this technology as well as to assess
its ability to provide both qualitative and quantitative data.
To determine whether steric hindrance might restrict acces-
sibility to the surface-bound DNA, the binding sites were
tested at the different positions described before, H58–H19
being closest to the microarray-linked residue, E58–E19 being
in central position and N58–N19 being in end-standing posi-
tion (Figure 1B). Terminal positions revealed higher binding
signals than the same sites in a central position (E58–E19).
Lower binding to the central position of the DNA immobilized
on the microarray may indicate that DNA linking to the sur-
face occurred not solely by the terminal N-link, but also by
amine residues within the DNA bases, as shown previously for
DNA immobilization on aldehyde surfaces (20). Overall, bind-
ing to PCR-amplified probes was similar to that observed with
the shorter oligonucleotides (O58–O19), except for probes
which do not display significant binding affinity, where bind-
ing was somewhat higher with the longer probes (Figure 2A).
Amplification of DNA probes of various length indicated that
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this residual binding increases with probe length, as expected
from non-specific interactions (data not shown).
Normalized binding to the high- and medium-affinity
probes increased with protein concentration and reached
saturation with 350 ng of purified protein, illustrating the
specific interaction of AP-2 with its binding sites (Figure 2B).
Fragments with little or no affinity (profile scores of 25 and
lower) also exhibited a gradual increase of signal with rising
protein concentrations but did not reach saturation, as expected
from non-specific interactions. Using amounts of AP-2 cor-
responding to 50% occupancy of the probe, we estimate that
8 ng of AP-2 binds 1 ng DNA with the microrarray, and 16 ng
is required with the gel shift assay. Thus, the two types of
assays are of similar sensitivity.
Next we assessed whether AP-2 would access and bind
equally well to various amounts of immobilized nucleic acids
Figure 2. AP-2 binding to double-stranded DNA microarray probes. (A) AP-2 DNA-binding specificity. Microarrays were spotted with probes in the form of 50 bp
oligonucleotides (O58–O19, black columns) or of 120 bp PCR products (grey columns) generated as described in the legend to Figure 1. Binding sites are located
either in central (EcoRV site, E58–E19) or in terminal (HincII, H58–H19 and NotI, N58–N19) position on the 120 bp probes. Probe numbers indicate the profile score
of the binding sites computed as in Figure 1. Microarrays were incubated with purified GST-AP-2 fusion and bound proteins were detected with Cy3-labeled
polyclonal antisera as described in Materials and methods. Binding activities determined from the Cy3 fluorescence were normalized to the Cy5 signal corresponding
to the spotted DNA. The white column indicates background binding to a control PCR fragment into which no AP-2 site has been inserted. Values depict the average
and SD of three data points. (B) Protein dose–response curves. Normalized binding activities were determined as above using the indicated amounts in nanograms of
GST-AP-2 protein. High-affinity sequences (matrix values>33) are given as closed symbols (diamonds N58, triangles N38, squares N33), and low-affinity sequences
(matrix values <25) are shown as open symbols (triangles N25, diamonds N19, circles control). (C) Binding activity as a function of DNA-spotting concentration.
DNA probes containing high- (E58), intermediate- (E33) or low-affinity (E19) sites were spotted in various concentrations as in Figure 1D and incubated with 70 ng of
purified GST-AP-2. The average and SD of three data points of normalized binding activities are displayed as for (A).
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in the standard range of DNA concentrations used for spotting
(100–500 ng/ml), or whether ‘crowding effects’ would be
observed. Binding normalized to the amount of DNA effect-
ively immobilized on the microarray shows little bias over the
concentration range (Figure 2C and Supplementary Figure 2).
This indicates that a similar fraction of the DNA is accessible
over the range of DNA concentrations, regardless of the actual
affinity of the site, and that robust measurements can be
achieved irrespective of the spotting conditions.
AP-2 binding to microarrays correlates with
profile prediction and gel shift results
To further evaluate the quality of the microarray-assessed
AP-2 binding to DNA, binding values were compared with
those predicted in silico from the profile score or those deter-
mined by the gel shift assay. For the 120 bp fragments with
target sequences in central position (E58–E19), high correla-
tion coefficients were obtained when comparing the micro-
array data with the profile score (0.96, Figure 3A) or with
binding values from gel shift experiments (0.97, Figure 3B).
Microarray data also compared well with in silico determined
profile scores when the binding sites were in end-standing
positions (H58–H19 and N58–N19), with correlation coeffi-
cients of 0.98–90.99 (Figures 3C and D). The higher correla-
tion coefficients obtained from probes displaying binding
sites at their extremity are consistent with the higher binding
affinities observed in microarray measurements.
Sequence-specific DNA binding was further confirmed by
conducting microarray competition assays in analogy to the gel
shift competition assays described above. Low amounts (5 ng)
of the specific competitor DNA O58 abolished detectable
binding (Supplementary Figure 3A), while 1 mg of non-specific
competitor DNA (O19) was unable to abolish binding (Sup-
plementary Figure 3B). These competition assays indicate that
binding to immobilized DNA on a microarray reflects specific
protein–DNA interaction by AP-2 as for the gel shift assay,
while providing a much higher data yield as multiple DNA
sequences are probed simultaneously.
Detection of AP-2 from extracts of breast cancer cells
Downregulation of AP-2 activity and/or its re-localization
from the cell nucleus to the cytoplasm correlate with increased
tumor malignancy and unfavorable prognosis for a wide vari-
ety of cancer types, including breast tumors (8–11). We there-
fore assessed whether the microarray technique might be
sensitive enough to detect low levels of AP-2 binding activity
from tumor cell nuclear extracts. In a first approach, we tran-
siently co-transfected HepG2 cells with CMV-promoter driven
AP-2 expression vector, as these cells express little or no
endogenous AP-2 (21). Nuclear proteins were extracted and
used for binding studies on microarrays as described above.
Whereas non-transfected cells showed little signal above back-
ground as expected, transfected HepG2 cells showed a binding
pattern over the various DNA probes that was similar to that
observed using the purified AP-2 protein (Figure 4A). Mixing
of the nuclear extract of non-transfected cells with the purified
protein also yielded binding patterns and levels similar to
those obtained with the purified protein alone, indicating that
Figure 3. Comparisons of relative AP-2 binding activities using in silico, in vitro and on-chip assays. Comparison between profile prediction scores and microarray
binding values using E19–E58 (A), H19–H58 (C) and N19–N58 (D) probes, determined as detailed in the legends to Figures 1 and 2. (B) displays a comparison of gel
shift and microarray binding values for the E19–E58 probes. Correlation coefficients are given in the top left corner of (A–D).
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the affinity of AP-2 for the different probes is not affected by
other cellular proteins. In further titrations, the detection limit
for AP-2 in the presence of total nuclear protein was set to a
2-fold signal increase between high-affinity binding sites
(E58) and the noise obtained with non-binding control probes
(Supplementary Figures 2B and 4). The detection limit
for AP-2 was found to lie around 100–200 pg, corresponding
to 2 fmol of the purified protein in the assay. Therefore,
meaningful and sensitive measurements can be performed
from crude nuclear cell extracts.
Next, the naturally occurring endogenous levels and affin-
ities of AP-2 were assessed in MCF-7 human breast cancer
cells, representing a tumor type where the AP-2a family mem-
ber used here is known to play a prominent role in carcino-
genesis. Although transcription factors are of low abundance,
the endogenous level was readily detectable using 10 mg of
total nuclear extract in a volume of 20 ml (Supplementary
Figure 2B). The relative binding affinities of non-purified
MCF-7 AP-2 to the various specific and non-specific probes
were analogous to those observed for the HepG2-expressed or
purified proteins (Figure 4B).
Considering that 20 pg of total protein is obtained
from one cell nucleus, there are 200 000 AP-2 molecules
per cell in this rather aggressive tumor type, as estimated from
the calibration curve shown in Supplementary Figure 4.
Thus, such microarrays may allow sensitive estimations of
the amounts of active DNA-binding proteins from minute
samples.
DISCUSSION
Gene expression is only one of the relevant aspects of
cell physiology, another being the misregulation of protein-
mediated cellular signaling pathways. The localization and
activity of low-abundance oncogenes such as DNA-binding
regulatory factors remain difficult to assess with DNA-only
approaches. Although proteomic analysis provides useful
complementary data, detection is still limited to a fraction
of the proteins present in crude cell extracts. Several recent
studies have used surface plasmon resonance (SPR) or PBM
technologies in conjunction with microarray-based binding
assays to analyze and model the DNA-binding sequence
specificity of purified transcription factors (1,2,22,23). Here,
we show that PBMs can also be used to develop sensitive and
reliable techniques for functional assays of DNA-binding
proteins from unfractionated cellular extracts.
The specificity of the assay can be assessed by comparing
the pattern of binding of the purified protein with those
obtained from transfected cells or with endogenous AP-2 in
tumor cells. A similar DNA-binding pattern was obtained
from all types of samples, illustrating the high specificity of
the microarray-based assay. Detection specificity relies on the
monoclonal antibody used to detect the transcription factor,
coupled to the analysis of a collection of binding sites of known
affinities to that protein. Therefore, spurious cross-reactivity of
the antibody with another DNA-binding protein can be ruled
out by analyzing the pattern of signals over a collection of
DNA sequences of known affinities, and the specificity of the
Figure 4. Microarray-based detection of sequence-specific AP-2 DNA-binding activity from human cell nuclear extracts. Normalized binding activities were
determined for the indicated microarray probes incubated with AP-2-containing nuclear extracts. Nuclear extracts consisted of 2 mg total proteins of HepG2
hepatocellular carcinoma cells, either non-transfected (closed bars) or transiently transfected with an AP-2 expression vector (open bars) [four data points, (A)], or of
10 mg total proteins from untransfected MCF-7 mammary gland carcinoma cells [n = 20, (B)].
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detection method does not rely merely on the interaction of the
antibody with the protein as in immunological assays.
The sensitivity of the assay allows the detection of very low
protein amounts, i.e. femtomoles of the AP-2 protein. Also,
a large number of DNA sequences can be analyzed in parallel
from culture or tissue samples. Thus, a few nanograms of
purified protein or micrograms of total protein extract suffice
for an assay of several hundred data points, while one
sequence is analyzed using low-throughput measurements
such as gel shift assays. In the dynamic range of protein con-
centrations, microarray-mediated binding measurements are
commensurate with the affinities determined by conventional
assays or computed in silico. Thus, double-stranded DNA
microarrays can provide an estimate of the relative affinities
of a purified transcription factor for a collection of DNA
sequences.
The AP-2 transcription factor analyzed in this study has a
protective role in several cancer types. For instance, it acts
by competing with activating factors for overlapping binding
sites in the promoters of oncogenes. In human melanoma,
transcriptional activator Sp1 is predominantly bound to the
PAR-1 promoter, a contributor to tumor invasion and meta-
stasis, whereas AP-2 occupies this promoter in non-metastatic
cells (10). Similarly, AP-2 acts as a tumor suppressor in
prostate cancer, where it competes with the transcriptional
activator Sp3 for binding to the VEGF promoter, thereby
repressing its expression (11). Changes in the localization
of AP-2 also modulate tumorigenicity. AP-2 proteins can be
relocated from the nucleus to the cytoplasm, and low nuclear
levels of AP-2 are associated with disease progression and
increased metastatic capability in breast cancer patients
(9,12). PBM testing of the relative activities of AP-2 and
competing proteins could therefore be used to rapidly analyze
prevalent cancer types.
Cancer type identification is currently based mainly on
histology, although identical histological features can be
observed from tumors that progresses rapidly in one patient
and slowly in another (e.g. prostate or breast cancer, or some
types of sarcoma). PBMs carry a potential predictive value for
functional/behavioral diagnosis with direct clinical impact.
Coupled to the detection of other DNA-binding proteins,
more general applications for the analysis of normal and
diseased cells can be envisioned. For instance, the aberrant
activity, location or expression of various transcription factors
has been linked to a growing number of diseases (24). In
normal cells, transcription factors usually interface signaling
pathways to the regulation of gene expression. This technique,
if coupled to the analysis of a collection of DNA-binding
proteins, may therefore probe the interface of the proteomic
and genomic worlds, opening a window on the cell’s regulome
and providing a snapshot of its regulatory status.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
ACKNOWLEDGEMENTS
We thank Dr R. Buettner for kindly providing the AP-2
expression vector, Dr P. Descombes for custom-made
microarrays and helpful discussions and Dr T. Williams and
Dr I. Stamenkovic for useful comments on the manuscript.
Equipment and expertise for microarray analysis were kindly
provided by the DNA array facility at Lausanne. This research
was supported by a special grant from the program in genomics
of the University of Lausanne, the FNRS and by the ISREC,
Switzerland. Funding to pay the Open Access publication
charges for this article was provided by the University of
Lausanne.
Conflict of interest statement. None declared.
REFERENCES
1. Linnell,J., Mott,R., Field,S., Kwiatkowski,D.P., Ragoussis,J. and
Udalova,I.A. (2004) Quantitative high-throughput analysis of
transcription factor binding specificities. Nucleic Acids Res., 32, e44.
2. Mukherjee,S., Berger,M.F., Jona,G., Wang,X.S., Muzzey,D., Snyder,M.,
Young,R.A. and Bulyk,M.L. (2004) Rapid analysis of the DNA-binding
specificities of transcription factors with DNA microarrays. Nature
Genet., 36, 1331–1339.
3. Mitchell,P.J., Wang,C. and Tjian,R. (1987) Positive and negative
regulation of transcription in vitro: enhancer-binding protein AP-2 is
inhibited by SV40 T antigen. Cell, 50, 847–861.
4. Zeng,Y.X., Somasundaram,K. and el-Deiry,W.S. (1997) AP2 inhibits
cancer cell growth and activates p21WAF1/CIP1 expression.
Nature Genet., 15, 78–82.
5. Bosher,J.M., Totty,N.F., Hsuan,J.J., Williams,T. and Hurst,H.C. (1996)
A family of AP-2 proteins regulates c-erbB-2 expression in mammary
carcinoma. Oncogene, 13, 1701–1707.
6. Jean,D., Gershenwald,J.E., Huang,S., Luca,M., Hudson,M.J.,
Tainsky,M.A. and Bar-Eli,M. (1998) Loss of AP-2 results in
up-regulation of MCAM/MUC18 and an increase in tumor growth and
metastasis of human melanoma cells. J. Biol. Chem., 273, 16501–16508.
7. Gaubatz,S., Imhof,A., Dosch,R., Werner,O., Mitchell,P., Buettner,R. and
Eilers,M. (1995) Transcriptional activation by Myc is under negative
control by the transcription factor AP-2. EMBO J., 14, 1508–1519.
8. Gee,J.M., Robertson,J.F., Ellis,I.O., Nicholson,R.I. and Hurst,H.C.
(1999) Immunohistochemical analysis reveals a tumor suppressor-like
role for the transcription factor AP-2 in invasive breast cancer.
J. Pathol., 189, 514–520.
9. Pellikainen,J., Kataja,V., Ropponen,K., Kellokoski,J., Pietilainen,T.,
Bohm,J., Eskelinen,M. and Kosma,V.M. (2002) Reduced nuclear
expression of transcription factor AP-2 associates with aggressive breast
cancer. Clin. Cancer Res., 8, 3487–3495.
10. Tellez,C., McCarty,M., Ruiz,M. and Bar-Eli,M. (2003) Loss of activator
protein-2alpha results in overexpression of protease-activated
receptor-1 and correlates with the malignant phenotype of human
melanoma. J. Biol. Chem., 278, 46632–46642.
11. Ruiz,M., Pettaway,C., Song,R., Stoeltzing,O., Ellis,L. and Bar-Eli,M.
(2004) Activator protein 2alpha inhibits tumorigenicity and represses
vascular endothelial growth factor transcription in prostate cancer cells.
Cancer Res., 64, 631–638.
12. Aqeilan,R.I., Palamarchuk,A., Weigel,R.J., Herrero,J.J., Pekarsky,Y.
and Croce,C.M. (2004) Physical and functional interactions between the
Wwox tumor suppressor protein and the AP-2gamma transcription factor.
Cancer Res., 64, 8256–8261.
13. Mohibullah,N., Donner,A., Ippolito,J.A. and Williams,T. (1999)
SELEX and missing phosphate contact analyses reveal flexibility within
the AP-2a protein: DNA binding complex. Nucleic Acids Res., 27,
2760–2769.
14. Roulet,E., Bucher,P., Schneider,R., Wingender,E., Dusserre,Y.,
Werner,T. and Mermod,N. (2000) Experimental analysis and computer
prediction of CTF/NFI transcription factor DNA binding sites.
J. Mol. Biol., 297, 833–848.
15. Durbin,R., Eddy,S., Krogh,A. and Mitchinson,G. (1988) Biological
sequence analysis. In Probabilistic Models of Proteins and Nucleic
Acids. Cambridge University Press, Cambridge, UK.
16. Roulet,E., Busso,S., Camargo,A.A., Simpson,A.J., Mermod,N. and
Bucher,P. (2002) High-throughput SELEX SAGE method for
quantitative modeling of transcription-factor binding sites.
Nat. Biotechnol., 20, 831–835.
e79 Nucleic Acids Research, 2005, Vol. 33, No. 8 PAGE 8 OF 9
17. Hilger-Eversheim,K., Moser,M., Schorle,H. and Buettner,R. (2000)
Regulatory roles of AP-2 transcription factors in vertebrate development,
apoptosis and cell-cycle control. Gene, 260, 1–12.
18. Bucher,P., Karplus,K., Moeri,N. and Hofmann,K. (1996) A flexible motif
search technique based on generalized profiles. Comput. Chem., 20, 3–23.
19. Ehret,G.B., Reichenbach,P., Schindler,U., Horvath,C.M., Fritz,S.,
Nabholz,M. and Bucher,P. (2001) DNA binding specificity of different
STAT proteins. Comparison of in vitro specificity with natural target
sites. J. Biol. Chem., 276, 6675–6688.
20. Diehl,F., Beckmann,B., Kellner,N., Hauser,N.C., Diehl,S. and
Hoheisel,J.D. (2002) Manufacturing DNA microarrays from unpurified
PCR products. Nucleic Acids Res., 30, e79.
21. Williams,T., Admon,A., Luscher,B. and Tjian,R. (1988)
Cloning and expression of AP-2, a cell-type-specific transcription
factor that activates inducible enhancer elements. Genes Dev., 2,
1557–1569.
22. Bulyk,M.L., Huang,X., Choo,Y. and Church,G.M. (2001) Exploring the
DNA-binding specificities of zinc fingers with DNA microarrays.
Proc. Natl Acad. Sci. USA, 98, 7158–7163.
23. Kyo,M., Yamamoto,T., Motohashi,H., Kamiya,T., Kuroita,T.,
Tanaka,T., Engel,J.D., Kawakami,B. and Yamamoto,M. (2004)
Evaluation of MafG interaction with Maf recognition element arrays
by surface plasmon resonance imaging technique. Genes Cells,
9, 153–164.
24. Zaidi,S.K., Young,D.W., Choi,J.Y., Pratap,J., Javed,A., Montecino,M.,
Stein,J.L., van Wijnen,A.J., Lian,J.B. and Stein,G.S. (2005) The dynamic
organization of gene-regulatory machinery in nuclear
microenvironments. EMBO Rep., 6, 128–133.
PAGE 9 OF 9 Nucleic Acids Research, 2005, Vol. 33, No. 8 e79
